Cardiff Oncology director granted 40,565 stock options
Cardiff Oncology director Renee P. Tannenbaum received a new stock option grant covering 40,565 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cardiff Oncology director Renee P. Tannenbaum received a new stock option grant covering 40,565 shares of common stock. These options have an exercise price of $1.59 per share and expire on June 11, 2036. Following this grant, she holds 209,331 derivative securities directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
Insider Trade Summary
Grant/Award: 40,565 shares
Grant/Award
1 txn
Insider
TANNENBAUM RENEE P
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 40,565 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options — 209,331 contracts (Direct)
Key Figures
Options granted: 40,565 stock options
Exercise price: $1.59 per share
Expiration date: June 11, 2036
+3 more
6 metrics
Options granted
40,565 stock options
Grant to director on June 11, 2026
Exercise price
$1.59 per share
Stock option strike price
Expiration date
June 11, 2036
Option expiration
Underlying shares
40,565 shares
Common stock underlying the options
Holdings after grant
209,331 derivative securities
Total options held following transaction
Transaction price per option
$0.00
Cost to recipient at grant
Key Terms
Stock Options, grant/award acquisition, derivative securities, exercise price, +1 more
5 terms
Stock Options financial
"security_title: "Stock Options""
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
grant/award acquisition financial
"transaction_action: "grant/award acquisition""
derivative securities financial
"total_shares_following_transaction: "209331.0000" derivativeTransactionCount"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
exercise price financial
"conversion_or_exercise_price: "1.5900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cardiff Oncology (CRDF) report for Renee P. Tannenbaum?
Cardiff Oncology reported that director Renee P. Tannenbaum received a grant of stock options for 40,565 shares of common stock. The award is compensation-related and not an open-market purchase or sale of existing shares.
What is the exercise price and term of the new CRDF stock options granted?
The granted stock options have an exercise price of $1.59 per share and expire on June 11, 2036. This gives the director a long-dated right to buy Cardiff Oncology common stock at that fixed price.
How many Cardiff Oncology derivative securities does the director hold after this Form 4?
After the reported grant, Renee P. Tannenbaum holds 209,331 derivative securities. These represent stock options tied to Cardiff Oncology common stock and provide potential future equity exposure if exercised.
Was the Cardiff Oncology (CRDF) Form 4 transaction a market buy or sell?
No, the Form 4 shows a grant or award acquisition of stock options, coded as “A.” It reflects equity compensation granted at no cost per option, not an open-market share purchase or sale.
What underlying security is covered by the new Cardiff Oncology options grant?
The stock option grant covers 40,565 shares of Cardiff Oncology common stock as the underlying security. If exercised at $1.59 per share, the options would convert into that number of common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates